SAN DIEGO--(BUSINESS WIRE)--PURE Bioscience (NASDAQ:PURE), creators of the patented silver dihydrogen citrate (SDC) antimicrobial, announced today that it has sold $2.376 million of its common stock in an unregistered private placement solely to non-affiliated accredited investors.
